Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, +16

New England Journal of Medicine

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, +15

Journal of Clinical Oncology

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, +4969

The Lancet

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, +4973

The Lancet

Covid-19 PandemicAntiviral TherapyClinical TrialsPlatform TrialMedicine +1

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, +4972

The Lancet

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Lucio Crinò, Federico Cappuzzo, Petr Zatloukal, +11

Journal of Clinical Oncology

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

Kōichi Goto, Yukito Ichinose, Yuichiro Ohe, +10

Journal of Thoracic Oncology

OncologySomatic VariantMedicinePathologyCirculating Free Dna +8

Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study)

Christie M. Ballantyne, Robert Weiss, Tiziano Moccetti, +4

The American Journal of Cardiology

Cardiovascular DiseaseAntihypertensive TherapyPharmacologyCardiovascular PharmacologyExplorer Study +5

Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)

Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo, +11

Journal of Thoracic Oncology

Advanced NsclcOncologyCancer ManagementClinical TrialsPharmacotherapy +4

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, +4972

The Lancet